# A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

> **NCT07334301** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Birmingham** · enrollment: 160 (estimated)

## Conditions studied

- Relapsed Neuroblastoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Dinutuximab beta
- **DRUG:** Irinotecan (drug)
- **DRUG:** Topotecan
- **DRUG:** Temozolomide (TMZ)
- **DRUG:** Temozolomide (TMZ)

## Key facts

- **NCT ID:** NCT07334301
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-11
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07334301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07334301, "A Multi-Arm, Platform Trial For Relapsed Neuroblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07334301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*